Format

Send to

Choose Destination
Curr Opin Otolaryngol Head Neck Surg. 2014 Apr;22(2):109-15. doi: 10.1097/MOO.0000000000000029.

Modern management of Merkel cell carcinoma.

Author information

1
ENT-Department, Head and Neck Surgery, Zurich, Switzerland.

Abstract

PURPOSE OF REVIEW:

Merkel cell carcinoma (MCC) is a rare, aggressive malignancy. Worldwide incidence is increasing and roughly 50% of patients present with a primary lesion in the head and neck. This article discusses recent advances and treatment recommendations.

RECENT FINDINGS:

Recent research has focused on the carcinogenesis of MCC, in particular the role of Merkel cell polyoma virus (MCPyV) and its surrogate marker large T-antigen. Together with cytokeratin 20 (CK20), other biomarkers like human insulin gene enhancer-binding protein islet-1 (ISL1) and transcription factor OCT4 may provide improved methods for diagnosis and ultimately, therapy.

SUMMARY:

This review summarizes recent findings on MCC pathogenesis with a special emphasis on the impact of MCPyV. It further presents an overview of clinical aspects, and discusses treatment standards and emerging perspectives.

PMID:
24463300
DOI:
10.1097/MOO.0000000000000029
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center